[go: up one dir, main page]

WO2006013445A3 - Thiazolidinedione derivatives as alpha adrenergic receptor antagonists - Google Patents

Thiazolidinedione derivatives as alpha adrenergic receptor antagonists Download PDF

Info

Publication number
WO2006013445A3
WO2006013445A3 PCT/IB2005/002247 IB2005002247W WO2006013445A3 WO 2006013445 A3 WO2006013445 A3 WO 2006013445A3 IB 2005002247 W IB2005002247 W IB 2005002247W WO 2006013445 A3 WO2006013445 A3 WO 2006013445A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
receptor antagonists
adrenergic receptor
benign prostatic
prostatic hyperplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002247
Other languages
French (fr)
Other versions
WO2006013445A2 (en
Inventor
Nitya Anand
Mohammad Salman
Somesh Sharma
Gobind Singh Kapkoti
Anita Chugh
Kamna Nanda
Pakala Kumara Savithru Sarma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2006013445A2 publication Critical patent/WO2006013445A2/en
Publication of WO2006013445A3 publication Critical patent/WO2006013445A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to alpha 1a and/or alpha 1d adrenergic receptor antagonists. Compounds described can function as alpha 1a and/or alpha 1d adrenergic receptor antagonists and can be used to treat diseases or disorders mediated through alpha 1a and/or alpha 1d adrenergic receptors. Compounds described can also be used to treat benign prostatic hyperplasia or related symptoms thereof. Compounds described can also be used to treat lower urinary tract symptoms associated with or without benign prostatic hyperplasia. Also described are processes to prepare the described compounds, as well as pharmaceutical compositions thereof and methods of treating benign prostatic hyperplasia or related symptoms thereof.
PCT/IB2005/002247 2004-07-28 2005-07-28 Thiazolidinedione derivatives as alpha adrenergic receptor antagonists Ceased WO2006013445A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1401DE2004 2004-07-28
IN1401/DEL/2004 2004-07-28

Publications (2)

Publication Number Publication Date
WO2006013445A2 WO2006013445A2 (en) 2006-02-09
WO2006013445A3 true WO2006013445A3 (en) 2006-04-27

Family

ID=35610048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002247 Ceased WO2006013445A2 (en) 2004-07-28 2005-07-28 Thiazolidinedione derivatives as alpha adrenergic receptor antagonists

Country Status (1)

Country Link
WO (1) WO2006013445A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
US6316437B1 (en) * 1999-09-30 2001-11-13 Merck & Co., Inc. Spirohydantoin compounds and uses thereof
US6420366B1 (en) * 1997-11-13 2002-07-16 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[N-(αω-dicarboximido)]-alkanes useful as uro-selective α1-adrenoceptor blockers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
US6420366B1 (en) * 1997-11-13 2002-07-16 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[N-(αω-dicarboximido)]-alkanes useful as uro-selective α1-adrenoceptor blockers
US6316437B1 (en) * 1999-09-30 2001-11-13 Merck & Co., Inc. Spirohydantoin compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. M. DIPARDO ET AL.: "Cyclic Imides as Potent and Selective alpha-1A Adrenergic Receptor Antagonists", BIOORG. MED. CHEM. LETT., vol. 11, no. 14, 2001, pages 1959 - 1962, XP002364483 *

Also Published As

Publication number Publication date
WO2006013445A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2004087649A3 (en) Benodiazepine spirohydantoin cgrp receptor antagonists
WO2007061763A3 (en) Indole orexin receptor antagonists
WO2004082602A3 (en) Carboxamide spirohydantoin cgrp receptor antagonists
WO2007126935A3 (en) Diazepan orexin receptor antagonists
WO2005072308A3 (en) Cgrp receptor antagonists
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
WO2006099268A3 (en) Cgrp receptor antagonists
WO2007146349A3 (en) Cgrp receptor antagonists
DK1551803T3 (en) Azabicyclo derivatives as muscarinic receptor antagonists
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
WO2007061677A3 (en) Spirolactam aryl cgrp receptor antagonists
WO2006047196A3 (en) Cgrp receptor antagonists
WO2007016087A3 (en) Heterocyclic benzodiazepine cgrp receptor antagonists
SG166106A1 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
WO2007067511A3 (en) Morpholine carboxamide prokineticin receptor antagonists
WO2006050045A3 (en) Inhibitors of jun n-terminal kinases for treating glaucomatous retinopathy and ocular diseases
ZA201001467B (en) Novel heterocyclic compounds as mglu5 antagonists
WO2007081995A3 (en) Urotensin ii receptor antagonists
WO2006041830A3 (en) Cgrp receptor antagonists
WO2007061696A3 (en) Spirolactam bicyclic cgrp receptor antagonists
WO2007061692A3 (en) Spirolactam tricyclic cgrp receptor antagonists
WO2007019234A3 (en) Aminoethane sulfonamide orexin receptor antagonists
WO2007061694A3 (en) Spirohydantoin tricyclic cgrp receptor antagonists
WO2006120478A3 (en) Quinoline derivatives as neurokinin receptor antagonists
WO2004067510A8 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase